Bruker Co. (NASDAQ:BRKR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Bruker Co. (NASDAQ:BRKRGet Free Report) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $83.44.

A number of analysts have recently issued reports on the stock. Bank of America reduced their price target on shares of Bruker from $95.00 to $90.00 and set a “buy” rating for the company in a research report on Monday, May 20th. Stifel Nicolaus decreased their target price on shares of Bruker from $81.00 to $77.00 and set a “hold” rating for the company in a research note on Monday, May 20th. Jefferies Financial Group initiated coverage on shares of Bruker in a research note on Monday, June 3rd. They issued a “buy” rating and a $85.00 price target on the stock. StockNews.com downgraded Bruker from a “buy” rating to a “hold” rating in a research note on Tuesday, May 21st. Finally, The Goldman Sachs Group cut their price target on Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a research note on Tuesday.

Get Our Latest Stock Analysis on BRKR

Bruker Stock Performance

Bruker stock opened at $61.25 on Friday. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.81 and a quick ratio of 0.91. The company has a market cap of $8.90 billion, a P/E ratio of 22.27, a price-to-earnings-growth ratio of 2.10 and a beta of 1.20. Bruker has a fifty-two week low of $53.79 and a fifty-two week high of $94.86. The firm’s 50 day simple moving average is $68.56 and its 200-day simple moving average is $76.76.

Bruker (NASDAQ:BRKRGet Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The medical research company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.07. The firm had revenue of $721.70 million for the quarter, compared to analysts’ expectations of $729.88 million. Bruker had a net margin of 13.38% and a return on equity of 27.31%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.64 EPS. As a group, equities research analysts predict that Bruker will post 2.66 EPS for the current year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 17th. Shareholders of record on Monday, June 3rd were given a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, June 3rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.33%. Bruker’s payout ratio is currently 7.27%.

Hedge Funds Weigh In On Bruker

A number of institutional investors have recently modified their holdings of the company. Linden Thomas Advisory Services LLC grew its stake in Bruker by 16.8% in the 2nd quarter. Linden Thomas Advisory Services LLC now owns 19,357 shares of the medical research company’s stock valued at $1,235,000 after buying an additional 2,784 shares during the last quarter. CWM LLC grew its position in shares of Bruker by 165.4% in the second quarter. CWM LLC now owns 4,777 shares of the medical research company’s stock valued at $305,000 after purchasing an additional 2,977 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Bruker by 40.7% in the first quarter. EverSource Wealth Advisors LLC now owns 858 shares of the medical research company’s stock valued at $81,000 after purchasing an additional 248 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its position in shares of Bruker by 0.6% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 307,040 shares of the medical research company’s stock worth $28,689,000 after purchasing an additional 1,844 shares during the last quarter. Finally, Cetera Advisors LLC bought a new stake in Bruker during the 1st quarter valued at approximately $693,000. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

(Get Free Report

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Featured Articles

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.